摘要
目的探讨替罗非班在脑梗死溶栓治疗中的有效性和安全性。方法收集2016—2019年南阳南石医院救治的61例脑梗死患者的临床资料,均在溶栓24 h内病情加重而给予替罗非班治疗,并筛选出单纯静脉溶栓的患者61例进行疗效对照。结果试验组有效率57.4%,对照组有效率24.6%,2组有效率比较差异有统计学意义(P<0.05)。结论替罗非班是一种安全有效的治疗脑梗死溶栓后病情进展的药物。
Objective To investigate the efficacy and safety of tirofiban in thrombolysis of cerebral infarction.Methods The clinical data of 61 patients with cerebral infarction treated in Nanyang nanshai hospital from 2016 to 2019 were collected.Tirofiban was given to treat the patients with aggravation within 24 hours after thrombolysis,and 61 patients with simple intravenous thrombolysis were selected for efficacy control.Results The effective rate was 57.4% in the experimental group and 24.6% in the control group.Conclusion Tirofiban is a safe and effective drug for the treatment of cerebral infarction after thrombolysis.
作者
陈宏涛
史丽
CHEN Hongtao;SHI Li(Nanyang Nanshi Hospital Affiliated to Henan University,Nanyang 473000,China)
出处
《中国实用神经疾病杂志》
2020年第13期1173-1176,共4页
Chinese Journal of Practical Nervous Diseases
基金
2019年度河南省部共建医学科技攻关计划(编号:SB201901056)。
关键词
脑梗死
溶栓
替罗非班
阿司匹林
氯吡格雷
Cerebral Infarction
Thrombolysis
Tirofiban
Aspirin
Clopidogrel
